Sihuan Pharmaceutical Sees Aesthetics and Biopharma Growth Amid Overall Revenue Dip
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a leading pharmaceutical company in China, has released...
Finanical Reports
Sichuan Kelun-Biotech Reports 32.2% Revenue Growth in 2024 H1, Driven by MSD Partnership
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced its financial results for the first...
Harbour BioMed’s 2024 H1 Revenues Decline Amid R&D Optimization and Pipeline Advancements
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
MicuRx Pharmaceuticals Reports 44% Revenue Growth and Increased R&D Spending in 2024 H1
SHANGHAI—MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has released its financial report...
Junshi Biosciences Logs 17.37% Revenue Growth in 2024H1, Fueled by Loqtorzi Sales Surge
SHANGHAI—Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its financial results for...
MicroPort Medical Reports 17% Revenue Growth in 2024H1, Driven by Subsidiaries’ Performance
HONG KONG—MicroPort Medical Science and Technology Co., Ltd (HKG: 0853), a leading medical device company,...
Dizal Pharmaceutical’s Financial Turnaround Continues with 33% Net Loss Reduction in H1 2024
Dizal Pharmaceutical Co., Ltd, a pharmaceutical entity listed in Shanghai (SHA: 688192), has unveiled its...
Mindray Bio-Medical Electronics Reports 11.12% YOY Revenue Growth in 2024H1
SHENZHEN—Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for the first...
Hua Medicine’s 2024H1 Revenues Surge on HuaTangNing Sales; Path to Profitability in Sight
HONG KONG—Hua Medicine (HKG: 2552), a China-based pharmaceutical company, has announced its financial results for...
Innovent Biologics Reports 46.3% YOY Revenue Growth and Expands Portfolio with New Approvals and NDAs
Innovent Biologics, Inc., a leading biopharmaceutical company based in China and listed on the Hong...
Luye Pharma Group’s 2024H1 Revenue and Net Profits Surge, Driven by Oncology and CNS Therapy Revenues
Luye Pharma Group, a China-based pharmaceutical company listed in Hong Kong (HKG: 2186), has reported...
Asieris Pharmaceuticals Reports Explosive 103,397.96% YOY Revenue Growth in 2024H1 Financial Report
Asieris Pharmaceuticals, a China-based urogenital cancer specialist listed on the Shanghai Stock Exchange (SHA: 688176),...
Online Pharmacy Service Drives Jianke.com’s Revenue Growth in H1 2024 Amid Diverse Business Segments
Jianke.com, a China-based smart healthcare service platform, has unveiled its financial report for the first...
Everest Medicines Reports 158% Revenue Growth in 2024 H1, Driven by Pharmaceutical Sales and Operational Efficiency
Everest Medicines, a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1952),...
Shanghai Fosun Pharmaceutical Reports 5.31% YOY Revenue Growth and Strong R&D Investment in 2024H1 Report
Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and...
Luye Pharma’s Subsidiary Boan Bio Reports 2024H1 Revenue Growth and First Full Year of Profitability
Luye Pharma Group, a Chinese pharmaceutical company listed in Hong Kong (HKG: 2186), has announced...
Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition
Walvax Biotechnology Co., Ltd, a Chinese vaccine manufacturer listed on the Shenzhen Stock Exchange (SHE:...
BeiGene Positions for Global Growth with Strong Half-Year Results and R&D Investment
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) reported robust second-quarter 2024 results, highlighting significant corporate...
Shanghai Henlius Biotech Reports 9.8% YOY Revenue Growth and Continued Profitability in 2024H1 Financial Report
Shanghai Henlius Biotech Inc., a biopharmaceutical company based in China and listed on the Hong...
MicroPort Endovascular MedTech Reports 26.63% YOY Revenue Growth and Strong R&D Investment in 2024H1
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese endovascular device manufacturer, has reported...